4 assets in Bruton-Type Agammaglobulinemia

Therapeutic assets addressing Bruton-Type Agammaglobulinemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab Bruton-Type Agammaglobulinemia	Washington University School of Medicine	P2	CCC (53)
Fludarabine Bruton-Type Agammaglobulinemia	Washington University School of Medicine	P2	CCC (53)
Melphalan Bruton-Type Agammaglobulinemia	Washington University School of Medicine	P2	CCC (53)
Thiotepa Bruton-Type Agammaglobulinemia	Washington University School of Medicine	P2	CCC (53)